Cytokinetics draws new Buy from Citi on aficamten potential
Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...
Citi sets $86 price target on Cytokinetics stock with buy rating
Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Envista Holdings (NVST)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK – Research Report) and ...
Cytokinetics initiated with a Buy at Citi
Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...
JMP Securities maintains Cytokinetics stock with $78 target
JMP Securities reiterated its Market Outperform rating and $78.00 price target for Cytokinetics shares (NASDAQ:CYTK). This affirmation comes despite the stock experiencing a significant drop on ...